Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ondansetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.96 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.96 |
| ▸ | HTR3B | O95264 | 1/20 | 0.96 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.96 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.96 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.96 |
| ▸ | HTR2B | P41595 | 1/20 | 0.96 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.96 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.96 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.96 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.96 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.96 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ondansetron SCHEMBL27599152 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29387592 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL7217414 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL157565 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL7217409 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL8153849 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL5123895 | 0.99 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL6186951 | 0.99 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29607040 | 0.99 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (S)-Ondansetron SCHEMBL25017 | 0.99 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6127 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4729123-A2 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | Alto Neuroscience, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | ASTELLAS PHARMA INC (JP) | 2026-03-12 | — | — | US | claimed |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE INC (US) | 2026-03-12 | — | — | US | claimed |
| US-12521374-B1 | Combination therapy for a dopamine agonist | ALTO NEUROSCIENCE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| US-20250329454-A1 | DIAGNOSTIC INDICES FOR NEURODEGENERATIVE CONDITIONS | CHASE THERAPEUTICS CORP (US) | 2025-10-23 | — | — | US | claimed |
| US-20250288545-A1 | NEOSTIGMINE COMBINATIONS AND COMPOSITIONS | DAS-MG, INC. | 2025-09-18 | — | — | US | claimed |
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | RICHTER VIRGINIA PACT (US) | 2002-03-21 | — | — | US | claimed |
| US-20010039952-A1 | ULTRASOUND ENHANCED CHEMOTHERAPY | WALTER A. HACKER, PH. D | 2001-11-15 | — | — | US | claimed |
| US-6308714-B1 | Ultrasound enhanced chemotherapy | CORAJE, INC. | 2001-10-30 | — | — | US | claimed |
| WO-2001054667-A1 | ELECTROSPUN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2001019371-A1 | TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF 5-HYDROXYTRYPTAMINE RECEPTOR/α2 ADRENERGIC RECEPTOR ANTAGONIST COMPOSITIONS | RICHTER, REED (US) | 2001-03-22 | — | — | WO | claimed |
| US-5622720-A | USING AQUEOUS SOLVENT MIXTURE | GLAXO GROUP LIMITED (GB) | 1997-04-22 | — | — | US | claimed |
| US-5344658-A | Crystallization from solvent by drying with heat treatment and vacuum | GLAXO GROUP LIMITED (GB) | 1994-09-06 | — | — | US | claimed |
| EP-0415522-B1 | Process for reducing the crystal size of ondansetron hydrochloride dihydrate | GLAXO GROUP LTD (GB) | 1994-08-24 | — | — | EP | claimed |
| EP-0415522-A1 | Process for reducing the crystal size of ondansetron hydrochloride dihydrate | GLAXO GROUP LIMITED (GB) | 1991-03-06 | — | — | EP | claimed |
| EP-0411900-A2 | Medicaments for the treatment of bulimia | GLAXO GROUP LIMITED (GB) | 1991-02-06 | — | — | EP | claimed |